Vaxcyte

PCVX

Capitalización de mercado USD 10 mil M

The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.

Vaxcyte remains a 'Strong Buy' after robust phase 3 OPUS-1 results for VAX-31, demonstrating non-inferiority to Prevnar 20 and Capvaxive in adults. The company offers significant upside with multiple 2027 catalysts: OPUS-2 and OPUS-3 phase 3 data for VAX-31 in adults in the 1st half of 2027 and phase 2 infant data. VAX-31 targets broader pneumococcal strain coverage versus current vaccines, addressing emerging serotypes and aiming for 95% adult IPD coverage.

Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.

Vaxcyte NASDAQ: PCVX said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults.

SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock, and expects to grant the underwriters a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes solely to cover over-allotments. The completion of the common stock and pre-funded warrant offering will not be contingent on the completion of the note offering, and the completion of the note offering will not be contingent on the completion of the common stock and pre-funded warrant offering. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when either offering may be completed, or as to the actual size or terms of either offering.

Vaxcyte, Inc. (PCVX) Discusses Top Line Results From OPUS-1 Phase 3 Trial of VAX-31 Pneumococcal Vaccine Candidate Transcript

Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete with Pfizer's Prevnar 20 and Merck's Capvaxive in the adult pneumococcal vaccine market, which Jefferies estimates could reach $3 billion to $6 billion or more.

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.

Vaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck.